In the healthy state, T cells are genetically programmed to survey and protect the body from infectious agents, environmental stressors, and malignancy. In the process of development and ...

Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly ...

Figure 1: FoxP3 immunoperoxidase stain (brown) of regulatory T cells in cutaneous T-cell lymphoma. Note the smaller nuclei of FoxP3 + cells compared with tumor cells (arrows). Full size image ...

"Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial" was originally created and published by ...

Citius is seeking approval in the US to treat patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) – a form of non-Hodgkin lymphoma – after at least one prior systemic therapy.

A new systematic review reveals promising results for oncolytic viral therapy in treating nonmelanoma skin cancers and ...

and potentially cutaneous T-cell lymphoma. All of these diseases have macrophage components and may show a beneficial response to local cutaneous therapy with immunotoxins such as these.

It is being tested in clinical trials for cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma. The FDA’s ...

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

Soligenix is enrolling patients in its FLASH2 study, with a formal interim analysis anticipated early in 2026. <li /> SNGX's HyBryte is a ...